This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human CD2 / SRBC Protein, His Tag (MALS verified)
catalog :
CD2-H5226
quantity :
50 ug, 1 mg
price :
350 USD, 2200 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
CD2-H5226
product name :
Human CD2 / SRBC Protein, His Tag (MALS verified)
quantity :
50 ug, 1 mg
price :
350 USD, 2200 USD
quantity & price :
$350/50ug,$2200/1mg
target :
CD2
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human CD2, His Tag (CD2-H5226) is expressed from human 293 cells (HEK293). It contains AA Lys 25 - Asp 209 (Accession # AAH33583).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human CD2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
T-cell surface antigen CD2 is also known as Erythrocyte receptor, LFA-2, LFA-3 receptor, Rosette receptor, T-cell surface antigen T11/Leu-5 and SRBC, is a single-pass type I membrane protein found on the surface of T cells and natural killer (NK) cells. CD2 is a member of the immunoglobulin superfamily. CD2 / SRBC contains 1 Ig-like C2-type (immunoglobulin-like) domain and 1 Ig-like V-type (immunoglobulin-like) domain. CD2 / SRBC interacts with other adhesion molecules, such as lymphocyte function-associated antigen-3 (LFA-3 / CD58) in humans, or CD48 in rodents, which are expressed on the surfaces of other cells. In addition to its adhesive properties, CD2 also acts as a co-stimulatory molecule on T and NK cells. CD2 is a specific marker for T cells and NK cells, and can therefore be used in immunohistochemistry to identify the presence of such cells in tissue sections.
References :
(1) Wilkins A., et al., 2003, Curr Protein Pept Sci 4 (5): 367–73.
(2) Yang J., et al., 2001, Curr Protein Pept Sci 2 (1): 1–17.
(3) Bodian D.L., et al., 1994, Structure 2:755-766.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments